CA2982536C - Antibodies, compositions, and immunohistochemistry methods for detecting c4.4a - Google Patents

Antibodies, compositions, and immunohistochemistry methods for detecting c4.4a Download PDF

Info

Publication number
CA2982536C
CA2982536C CA2982536A CA2982536A CA2982536C CA 2982536 C CA2982536 C CA 2982536C CA 2982536 A CA2982536 A CA 2982536A CA 2982536 A CA2982536 A CA 2982536A CA 2982536 C CA2982536 C CA 2982536C
Authority
CA
Canada
Prior art keywords
seq
antibody
amino acids
sample
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2982536A
Other languages
English (en)
French (fr)
Other versions
CA2982536A1 (en
Inventor
Fernando Jose Rebelo Do Couto
Zhiming Liao
Yifei Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ventana Medical Systems Inc
Original Assignee
Ventana Medical Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventana Medical Systems Inc filed Critical Ventana Medical Systems Inc
Publication of CA2982536A1 publication Critical patent/CA2982536A1/en
Application granted granted Critical
Publication of CA2982536C publication Critical patent/CA2982536C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2982536A 2015-04-17 2016-04-13 Antibodies, compositions, and immunohistochemistry methods for detecting c4.4a Active CA2982536C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562149239P 2015-04-17 2015-04-17
US62/149,239 2015-04-17
PCT/EP2016/058135 WO2016166169A1 (en) 2015-04-17 2016-04-13 Antibodies, compositions, and immunohistochemistry methods for detecting c4.4a

Publications (2)

Publication Number Publication Date
CA2982536A1 CA2982536A1 (en) 2016-10-20
CA2982536C true CA2982536C (en) 2023-04-18

Family

ID=55702016

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2982536A Active CA2982536C (en) 2015-04-17 2016-04-13 Antibodies, compositions, and immunohistochemistry methods for detecting c4.4a

Country Status (6)

Country Link
US (2) US10948493B2 (https=)
EP (1) EP3283522A1 (https=)
JP (1) JP6720208B2 (https=)
AU (1) AU2016249839B2 (https=)
CA (1) CA2982536C (https=)
WO (1) WO2016166169A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016166169A1 (en) * 2015-04-17 2016-10-20 Spring Bioscience Corporation Antibodies, compositions, and immunohistochemistry methods for detecting c4.4a
CN111349164B (zh) * 2018-12-21 2023-05-26 艾比玛特医药科技（上海）有限公司 糖基磷脂酰肌醇锚定糖蛋白（c4.4a）的单克隆抗体及其应用
EP4351602A4 (en) * 2021-06-11 2025-07-30 Memorial Sloan Kettering Cancer Center UPAR-TARGETING ANTIGEN-RECOGNIZING RECEPTORS AND THEIR USES
IL315431A (en) * 2022-03-16 2024-11-01 Pentixapharm Ag Antibodies against lypd3
EP4536278A2 (en) 2022-06-07 2025-04-16 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates
CN116086919B (zh) * 2023-02-20 2024-01-26 深圳裕策生物科技有限公司 一种肺癌和/或胰腺癌样本的染色方法及试剂盒
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1220919A2 (en) 1999-09-29 2002-07-10 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Metastasis-associated antigen c4.4a
US6649138B2 (en) 2000-10-13 2003-11-18 Quantum Dot Corporation Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
US20020083888A1 (en) 2000-12-28 2002-07-04 Zehnder Donald A. Flow synthesis of quantum dot nanocrystals
US6670113B2 (en) 2001-03-30 2003-12-30 Nanoprobes Enzymatic deposition and alteration of metals
EP1409240B1 (en) 2001-07-20 2012-05-09 Life Technologies Corporation Luminescent nanoparticles and methods for their preparation
EP1532175B1 (en) 2002-03-22 2012-10-17 Aprogen, Inc. Humanized antibody and process for preparing the same
US7642064B2 (en) 2003-06-24 2010-01-05 Ventana Medical Systems, Inc. Enzyme-catalyzed metal deposition for the enhanced detection of analytes of interest
DK1636586T3 (da) 2003-06-24 2009-11-23 Ventana Med Syst Inc Enzymkatalyseret metaldeponering til foröget in situ-detektion af immunhistokemisker epitoper og nucleinsyresekvenser
WO2008063378A2 (en) 2006-11-01 2008-05-29 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
KR20170036814A (ko) * 2007-05-21 2017-04-03 앨더바이오 홀딩스 엘엘씨 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
WO2009040562A1 (en) * 2007-09-26 2009-04-02 Ucb Pharma S.A. Dual specificity antibody fusions
PT2510012T (pt) * 2009-12-09 2017-07-13 Bayer Pharma AG Anticorpos anti-c4.4a e utilizações dos mesmos
WO2011158883A1 (ja) 2010-06-15 2011-12-22 国立大学法人大阪大学 癌予後判定可能な抗体、および癌予後判定方法
KR102023496B1 (ko) 2011-04-21 2019-09-20 시애틀 지네틱스, 인크. 신규 결합제-약물 콘주게이트 (adc) 및 그의 용도
CA2834535A1 (en) * 2011-04-29 2012-11-01 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
US20120295803A1 (en) 2011-05-16 2012-11-22 The Regents Of The University Of Michigan Lung cancer signature
KR20150013935A (ko) 2012-06-08 2015-02-05 갓코 호진 긴키 다이가쿠 트랜스포터에 대한 항체 및 이의 용도
WO2014183119A1 (en) 2013-05-10 2014-11-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Molecular imaging probes for lung cancer inoperative guidance
WO2014186878A1 (en) * 2013-05-24 2014-11-27 Cashman Neil R Cell senescence markers as diagnostic and therapeutic targets
US10428159B2 (en) * 2014-09-09 2019-10-01 Board Of Regents, The University Of Texas System Blocking monoclonal antibodies to AGR2 and its receptor C4.4A
WO2016166169A1 (en) * 2015-04-17 2016-10-20 Spring Bioscience Corporation Antibodies, compositions, and immunohistochemistry methods for detecting c4.4a

Also Published As

Publication number Publication date
AU2016249839A1 (en) 2017-09-21
US20180031566A1 (en) 2018-02-01
US10948493B2 (en) 2021-03-16
AU2016249839B2 (en) 2021-09-09
US11719699B2 (en) 2023-08-08
CA2982536A1 (en) 2016-10-20
JP6720208B2 (ja) 2020-07-08
JP2018515071A (ja) 2018-06-14
EP3283522A1 (en) 2018-02-21
US20210164985A1 (en) 2021-06-03
WO2016166169A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
US11719699B2 (en) Antibodies, compositions, and immunohistochemistry methods for detecting C4.4a
JP6445467B2 (ja) 抗ｐ４０抗体システムおよび方法
JP6324970B2 (ja) 抗ウロプラキンｉｉ抗体システムおよび方法
WO2014165422A1 (en) Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
US20160370370A1 (en) Systems and Methods for Anti-PAX8 Antibodies
JP2016500659A5 (https=)
CN108700586B (zh) 用于评估癌症发生的风险的组合物和方法
US20240393338A1 (en) Tibtech compositions and methods for detecting cdh17
US11561222B2 (en) Method for diagnosis of bile duct cancer using methionyl-tRNA synthetase in bile duct cell
JP2022128212A (ja) モノクローナル抗体、サイトケラチン１８フラグメントの測定試薬、試薬キットおよび測定方法
EP3677910B1 (en) Diagnosing pancreatic cancer using methionyl-trna synthetase and ck19
Thangaiyan et al. Functional characterization of novel anti-DEFA5 monoclonal antibody clones 1A8 and 4F5 in inflammatory bowel disease colitis tissues
US20210238305A1 (en) Antibody for her2 concomitant diagnosis immunohistochemical detection and application thereof
Moonen et al. Development and verification of new monoclonal orthopedia homeobox (OTP) specific antibodies for pulmonary carcinoid diagnostics
Kim et al. Cytokeratin 20/p53 dual immunocytochemistry for improving the diagnostic accuracy of urine liquid-based cytology in the detection of urothelial neoplasm: A retrospective study
JP2018529946A (ja) 癌の検出方法
JP2013096783A (ja) 肺腺癌を判定するためのデータ検出方法、診断薬、及び診断用キット
US9127054B2 (en) Immunoassay of cofilin 1 protein
JP2004198313A (ja) 甲状腺腫瘍の診断用キット
JP2024042026A (ja) 治療薬による処置から利益を受けうる被験体を特定するためのサンドウィッチｅｌｉｓａ
HK40073614A (en) Compositions and methods for assessing the risk of cancer occurrence
HK1262633A1 (en) Compositions and methods for assessing the risk of cancer occurrence

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190124

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250326

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250326